Please login to the form below

Not currently logged in
Email:
Password:

Emend

This page shows the latest Emend news and features for those working in and with pharma, biotech and healthcare.

CHMP October meeting gives recommendations for Pfizer and MSD

CHMP October meeting gives recommendations for Pfizer and MSD

Merck Sharpe &Dohme's Emend (aprepitant) was further recommended for the prevention of nausea and vomiting in child chemotherapy patients from the age of 6 months to 12 years.

Latest news

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    Merck plans expanded filing for Emend this year. Nausea and vomiting therapy more effective than placebo in 1000-patient trial. ... Emend has been a solid product for Merck &Co, with sales last year rising 9% to reach $553m, but is approaching the end of

  • Breathing easier

    Aprepitant . Emend (Ono Pharmaceutical). Chemotherapy-induced nausea and vomiting . Japan. Sitagliptin . Galactiv (Ono Pharmaceutical).

  • Breathing life

    Aprepitant. Emend (Ono Pharmaceutical). Chemotherapy induced nausea and vomiting. Japan. Sitagliptin.

  • Cost of living

    For example, anti-nausea drugs in the NK-1 class such as Emend make chemotherapy more manageable for high-need patients, thereby improving the likelihood of success for the primary therapy.

  • Elan and J&JPRD submit NDA for novel Invega reformulation

    Rapamune (sirolimus), which is marketed by Wyeth: and the anti-emetic treatment Emend (aprepitant), which is marketed by Merck &Co.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics